### Highlights of This Issue 6107

#### SPECIAL FEATURES

**CCR Translations**

6109  
**High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?**  
John F. de Groot  
See article p. 6192

**CCR New Strategies**

6112  
**New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice**  
Jonathan W. Friedberg

**Molecular Pathways**

6118  
**The Two Faces of Interferon-γ in Cancer**  
M. Raza Zaidi and Glenn Merlino

6125  
**Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer’s Inflammatory Roots**  
Hasan Korkaya, Suling Liu, and Max S. Wicha

**Review**

6130  
**Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis**  
Christopher Lieu, John Heymach, Michael Overman, Hai Tran, and Scott Kopetz

**HUMAN CANCER BIOLOGY**

6140  
**Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras**  

### CANCER THERAPY: PRECLINICAL

**Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models**  
Benjamin D. Hedley, Jenny E. Chu, D. George Ormond, Michel S. Beausoleil, Alexandra Boasse, Alison L. Allan, and Anargyros Xenocostas

**Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Plasmacytoid Dendritic Cell Neoplasm**  
Alice Agliano, Ines Martin-Padura, Paolo Marighetti, Giuliana Gregato, Angelica Calleri, Celia Prior, Miriam Redrado, Alfonso Calvo, and Francesco Bertolini

**Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells**  

**Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor**  
Monica Bartucci, Rosanna Dattilo, Daniela Martinetti, Matilde Todaro, Giuseppina Zapparelli, Antonio Di Virgilio, Mauro Biffoni, Ruggero De Maria, and Ann Zeuner

**Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells**  
Louisa von Baumgarten, David Brucker, Anca Tiranieru, Yvonne Kienast, Stefan Grau, Steffen Burgold, Jochen Herms, and Frank Winkler

**Enhancement of Carboplatin-Mediated Lung Cancer Cell Killing by Simultaneous Disruption of Glutathione and Thioredoxin Metabolism**  
Melissa A. Fath, Iman M. Ahmad, Carmen J. Smith, Jacquelyn Spence, and Douglas R. Spitz
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Liqun Chen, Benjamin A. Mooso, Maitreyee K. Jathal, Anisha Madhav, Sherin D. Johnson, Elyse van Spyk, Margarita Mikhailova, Alexandra Zierenberg-Ripoll, Lingu Xu, Ruth L. Vinall, Ralph W. de Vere White, and Paramita M. Ghosh

Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation
Zhen-Bin Ding, Bo Hui, Ying-Hong Shi, Jian Zhou, Yuan-Fei Peng, Cheng-Yu Gu, Hua Yang, Guo-Ming Shi, Ai-Wu Ke, Xiao-Ying Wang, Kang Song, Zhi Dai, Ying-Hao Shen, and Jia Fan

Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles
Francesc Balaguer, Leticia Moreira, Juan Jose Lozano, Alexander Link, Georgina Ramirez, Yan Shen, Miriam Cuatrecasas, Mildred Arnold, Stephen J. Meltzer, Sapna Syngal, Elena Stoffel, Rodrigo Jover, Xavier Llor, Antoni Castells, C. Richard Boland, Meritxell Gironella, and Ajay Goel

Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
Inna Serganova, Asif Rizwan, Xiaohui Ni, Sunitha B. Thakur, Jelena Vider, James Russell, Ronald Blasberg, and Jason A. Koutcher

Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination
Andrew G. Schache, Triantafilios Liloglou, Janet M. Rink, Anastasia Filia, Terence M. Jones, Jon Sheard, Julia A. Woolgar, Timothy R. Hellwell, Asterios Triantafylou, Max Robinson, Philip Sloan, Colin Harvey-Woodworth, Daniel Sisson, and Richard J. Shaw

Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer
Ryohei Nishino, Atsushi Takano, Hideto Oshita, Nobuhiro Ishikawa, Hirohiko Akiyama, Hiroyuki Ito, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, and Yataro Daigo

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst, John P. Riley, Mark E. Dudley, and Steven A. Rosenberg

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, and Gregory J. Riely

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, Ludmila Prudkin, Jordi Andreu, Edith Rodriguez-Braun, Amparo Domingo, Jorge Guijarro, Cristina Gamez, Jordi Rodon, Serena Di Cosimo, Holly Brown, Jason Clark, James S. Hardwick, Robert A. Beckman, William D. Hanley, Karl Hsu, Emiliano Calvo, Susana Roselló, Ronald B. Langdon, and José Baselga

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, Jose Antonio Lopez-Martin, Jaume Capdevila, Luis van Beijsterveldt, Suso Platero, Brett Hall, Zhi-long Yuan, Roland Knoblauch, and Sen Hong Zhuang

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, and Vincent A. Miller
### Predictive Biomarkers and Personalized Medicine

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6329</td>
<td>Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients</td>
<td>Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdon-Celle, Friedrich Piller, Alain Morel, Valérie Gouilleux-Gruart, Celine Vignault-Desvignes, Herve Watier, Erick Gamelin, and Gilles Paintaud</td>
</tr>
<tr>
<td>6338</td>
<td>KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective</td>
<td>Patricia R. Blank, Holger Moch, Thomas D. Szucs, and Matthias Schwenkglenks</td>
</tr>
</tbody>
</table>

### About the Cover

Growth of experimental glioma imaged in real time by *in vivo* multiphoton microscopy. This allows the study of the characteristic pattern of glioma growth and angiogenesis, and morphologic and functional vascular changes in response to antiangiogenic treatment. The cover image shows an U87 glioma expressing RFP (red) and tumor vessels (green, FITC dextran) 30 days after brain implantation (tumor diameter 3 mm). The image represents a maximum intensity projection of the mouse brain up to a depth of 350 µm. For details, see the article by von Baumgarten and colleagues on page 6192 of this issue.